BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim S, Kim do H, Jung WH, Koo JS. Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer. Endocr Relat Cancer. 2013;20:339-348. [PMID: 23507704 DOI: 10.1530/erc-12-0398] [Cited by in Crossref: 70] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Marshall AD, van Geldermalsen M, Otte NJ, Lum T, Vellozzi M, Thoeng A, Pang A, Nagarajah R, Zhang B, Wang Q, Anderson L, Rasko JEJ, Holst J. ASCT2 regulates glutamine uptake and cell growth in endometrial carcinoma. Oncogenesis 2017;6:e367. [PMID: 28759021 DOI: 10.1038/oncsis.2017.70] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
2 Teixeira E, Silva C, Martel F. The role of the glutamine transporter ASCT2 in antineoplastic therapy. Cancer Chemother Pharmacol 2021;87:447-64. [PMID: 33464409 DOI: 10.1007/s00280-020-04218-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Cao MD, Lamichhane S, Lundgren S, Bofin A, Fjøsne H, Giskeødegård GF, Bathen TF. Metabolic characterization of triple negative breast cancer. BMC Cancer 2014;14:941. [PMID: 25495193 DOI: 10.1186/1471-2407-14-941] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 10.5] [Reference Citation Analysis]
4 Wang L, Zhang S, Wang X. The Metabolic Mechanisms of Breast Cancer Metastasis. Front Oncol 2020;10:602416. [PMID: 33489906 DOI: 10.3389/fonc.2020.602416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
5 Zhong X, Yao L, Xu L, Ma Q, Huang G, Yang M, Gao C, Cheng J, Zhou X, Li Q, Guo X. Comprehensive Analysis of Potential Correlation Between Solute Carrier 1A (SLC1A) Family and Lung Adenocarcinoma. IJGM 2022;Volume 15:2101-17. [DOI: 10.2147/ijgm.s350986] [Reference Citation Analysis]
6 Kim S, Lee Y, Koo JS. Differential expression of lipid metabolism-related proteins in different breast cancer subtypes. PLoS One. 2015;10:e0119473. [PMID: 25751270 DOI: 10.1371/journal.pone.0119473] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 9.3] [Reference Citation Analysis]
7 Cappelletti V, Iorio E, Miodini P, Silvestri M, Dugo M, Daidone MG. Metabolic Footprints and Molecular Subtypes in Breast Cancer. Dis Markers 2017;2017:7687851. [PMID: 29434411 DOI: 10.1155/2017/7687851] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
8 Mikó E, Kovács T, Sebő É, Tóth J, Csonka T, Ujlaki G, Sipos A, Szabó J, Méhes G, Bai P. Microbiome-Microbial Metabolome-Cancer Cell Interactions in Breast Cancer-Familiar, but Unexplored. Cells 2019;8:E293. [PMID: 30934972 DOI: 10.3390/cells8040293] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 15.3] [Reference Citation Analysis]
9 Kim YH, Jung WH, Koo JS. Expression of metabolism-related proteins in invasive lobular carcinoma: comparison to invasive ductal carcinoma. Tumour Biol 2014;35:10381-93. [PMID: 25053597 DOI: 10.1007/s13277-014-2345-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
10 Kim SK, Jung WH, Koo JS. Differential expression of enzymes associated with serine/glycine metabolism in different breast cancer subtypes. PLoS One 2014;9:e101004. [PMID: 24979213 DOI: 10.1371/journal.pone.0101004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
11 Edwards DN, Ngwa VM, Raybuck AL, Wang S, Hwang Y, Kim LC, Cho SH, Paik Y, Wang Q, Zhang S, Manning HC, Rathmell JC, Cook RS, Boothby MR, Chen J. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest 2021;131:140100. [PMID: 33320840 DOI: 10.1172/JCI140100] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
12 Zhang D, Xu X, Ye Q. Metabolism and immunity in breast cancer. Front Med 2021;15:178-207. [PMID: 33074528 DOI: 10.1007/s11684-020-0793-6] [Reference Citation Analysis]
13 Xie L, Huang R, Huang H, Liu X, Yu J. Transcriptomics and Metabolomics Identify Drug Resistance of Dormant Cell in Colorectal Cancer. Front Pharmacol 2022;13:879751. [DOI: 10.3389/fphar.2022.879751] [Reference Citation Analysis]
14 Zacharias NM, Baran N, Shanmugavelandy SS, Lee J, Lujan JV, Dutta P, Millward SW, Cai T, Wood CG, Piwnica-Worms D, Konopleva M, Bhattacharya PK. Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia. Mol Cancer Ther 2019;18:1937-46. [PMID: 31387889 DOI: 10.1158/1535-7163.MCT-18-0985] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
15 El-Ansari R, Craze ML, Alfarsi L, Soria D, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR. The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer. Breast Cancer Res Treat 2019;175:27-38. [PMID: 30671766 DOI: 10.1007/s10549-018-05111-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
16 van Geldermalsen M, Wang Q, Nagarajah R, Marshall AD, Thoeng A, Gao D, Ritchie W, Feng Y, Bailey CG, Deng N, Harvey K, Beith JM, Selinger CI, O'Toole SA, Rasko JE, Holst J. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene 2016;35:3201-8. [PMID: 26455325 DOI: 10.1038/onc.2015.381] [Cited by in Crossref: 239] [Cited by in F6Publishing: 233] [Article Influence: 34.1] [Reference Citation Analysis]
17 Yu W, Yang X, Zhang Q, Sun L, Yuan S, Xin Y. Targeting GLS1 to cancer therapy through glutamine metabolism. Clin Transl Oncol 2021. [PMID: 34023970 DOI: 10.1007/s12094-021-02645-2] [Reference Citation Analysis]
18 Zhang L, Sui C, Yang W, Luo Q. Amino acid transporters: Emerging roles in drug delivery for tumor-targeting therapy. Asian J Pharm Sci 2020;15:192-206. [PMID: 32373199 DOI: 10.1016/j.ajps.2019.12.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
19 Li X, Zhu H, Sun W, Yang X, Nie Q, Fang X. Role of glutamine and its metabolite ammonia in crosstalk of cancer-associated fibroblasts and cancer cells. Cancer Cell Int 2021;21:479. [PMID: 34503536 DOI: 10.1186/s12935-021-02121-5] [Reference Citation Analysis]
20 Kim HM, Kim DH, Jung WH, Koo JS. Metabolic phenotypes in primary unknown metastatic carcinoma. J Transl Med 2014;12:2. [PMID: 24387319 DOI: 10.1186/1479-5876-12-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
21 Sun WY, Choi J, Cha YJ, Koo JS. Evaluation of the Expression of Amine Oxidase Proteins in Breast Cancer. Int J Mol Sci. 2017;18. [PMID: 29261141 DOI: 10.3390/ijms18122775] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
22 Grinde MT, Hilmarsdottir B, Tunset HM, Henriksen IM, Kim J, Haugen MH, Rye MB, Mælandsmo GM, Moestue SA. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer. Breast Cancer Res 2019;21:61. [PMID: 31088535 DOI: 10.1186/s13058-019-1141-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
23 Craze ML, Cheung H, Jewa N, Coimbra NDM, Soria D, El-Ansari R, Aleskandarany MA, Wai Cheng K, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR. MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer. Br J Cancer 2018;118:258-65. [PMID: 29169183 DOI: 10.1038/bjc.2017.387] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 7.4] [Reference Citation Analysis]
24 Shafei MA, Flemban A, Daly C, Kendrick P, White P, Dean S, Qualtrough D, Conway ME. Differential expression of the BCAT isoforms between breast cancer subtypes. Breast Cancer 2021;28:592-607. [PMID: 33367952 DOI: 10.1007/s12282-020-01197-7] [Reference Citation Analysis]
25 Kim HM, Lee YK, Koo JS. Expression of glutamine metabolism-related proteins in thyroid cancer. Oncotarget 2016;7:53628-41. [PMID: 27447554 DOI: 10.18632/oncotarget.10682] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
26 Zhang J, Hochwald SN. The role of FAK in tumor metabolism and therapy. Pharmacol Ther 2014;142:154-63. [PMID: 24333503 DOI: 10.1016/j.pharmthera.2013.12.003] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 6.3] [Reference Citation Analysis]
27 Li Y, Feng R, Yu X, Li L, Liu Y, Zhang R, Chen X, Zhao Y, Liu Z. SLC35E2 promoter mutation as a prognostic marker of esophageal squamous cell carcinoma. Life Sci 2022;:120447. [PMID: 35247439 DOI: 10.1016/j.lfs.2022.120447] [Reference Citation Analysis]
28 Ulaner GA, Schuster DM. Amino Acid Metabolism as a Target for Breast Cancer Imaging. PET Clin 2018;13:437-44. [PMID: 30100081 DOI: 10.1016/j.cpet.2018.02.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
29 Demas DM, Demo S, Fallah Y, Clarke R, Nephew KP, Althouse S, Sandusky G, He W, Shajahan-Haq AN. Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer. Front Oncol 2019;9:686. [PMID: 31428575 DOI: 10.3389/fonc.2019.00686] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
30 Garibsingh RA, Otte NJ, Ndaru E, Colas C, Grewer C, Holst J, Schlessinger A. Homology Modeling Informs Ligand Discovery for the Glutamine Transporter ASCT2. Front Chem 2018;6:279. [PMID: 30137742 DOI: 10.3389/fchem.2018.00279] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
31 Narvaez CJ, Grebenc D, Balinth S, Welsh JE. Vitamin D regulation of HAS2, hyaluronan synthesis and metabolism in triple negative breast cancer cells. J Steroid Biochem Mol Biol 2020;201:105688. [PMID: 32360595 DOI: 10.1016/j.jsbmb.2020.105688] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Lucantoni F, Dussmann H, Prehn JHM. Metabolic Targeting of Breast Cancer Cells With the 2-Deoxy-D-Glucose and the Mitochondrial Bioenergetics Inhibitor MDIVI-1. Front Cell Dev Biol 2018;6:113. [PMID: 30255019 DOI: 10.3389/fcell.2018.00113] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
33 Ansari RE, Craze ML, Althobiti M, Alfarsi L, Ellis IO, Rakha EA, Green AR. Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. Br J Cancer 2020;122:94-101. [PMID: 31819174 DOI: 10.1038/s41416-019-0626-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
34 Wang R, Xiang W, Xu Y, Han L, Li Q, Dai W, Cai G. Enhanced glutamine utilization mediated by SLC1A5 and GPT2 is an essential metabolic feature of colorectal signet ring cell carcinoma with therapeutic potential. Ann Transl Med. 2020;8:302. [PMID: 32355746 DOI: 10.21037/atm.2020.03.31] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Yoon JK, Kim DH, Koo JS. Implications of differences in expression of sarcosine metabolism-related proteins according to the molecular subtype of breast cancer. J Transl Med 2014;12:149. [PMID: 24884785 DOI: 10.1186/1479-5876-12-149] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
36 Choi J, Kim ES, Koo JS. Expression of Pentose Phosphate Pathway-Related Proteins in Breast Cancer. Dis Markers 2018;2018:9369358. [PMID: 29682102 DOI: 10.1155/2018/9369358] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
37 Edwards DN, Ngwa VM, Wang S, Shiuan E, Brantley-Sieders DM, Kim LC, Reynolds AB, Chen J. The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ. Sci Signal 2017;10:eaan4667. [PMID: 29208682 DOI: 10.1126/scisignal.aan4667] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 8.4] [Reference Citation Analysis]
38 Baumann J, Kokabee M, Wong J, Balasubramaniyam R, Sun Y, Conklin DS. Global metabolite profiling analysis of lipotoxicity in HER2/neu-positive breast cancer cells. Oncotarget 2018;9:27133-50. [PMID: 29930756 DOI: 10.18632/oncotarget.25500] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
39 Ogrodzinski MP, Teoh ST, Lunt SY. Metabolomic profiling of mouse mammary tumor-derived cell lines reveals targeted therapy options for cancer subtypes. Cell Oncol (Dordr) 2020;43:1117-27. [PMID: 32691367 DOI: 10.1007/s13402-020-00545-1] [Reference Citation Analysis]
40 Delgir S, Ilkhani K, Safi A, Rahmati Y, Montazari V, Zaynali-Khasraghi Z, Seif F, Bastami M, Alivand MR. The expression of miR-513c and miR-3163 was downregulated in tumor tissues compared with normal adjacent tissue of patients with breast cancer. BMC Med Genomics 2021;14:180. [PMID: 34233668 DOI: 10.1186/s12920-021-01029-3] [Reference Citation Analysis]
41 Sun WY, Kim HM, Jung WH, Koo JS. Expression of serine/glycine metabolism-related proteins is different according to the thyroid cancer subtype. J Transl Med 2016;14:168. [PMID: 27277113 DOI: 10.1186/s12967-016-0915-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
42 Park JH, Pyun WY, Park HW. Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets. Cells 2020;9:E2308. [PMID: 33081387 DOI: 10.3390/cells9102308] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
43 Woo Y, Lee HJ, Jung YM, Jung YJ. mTOR-Mediated Antioxidant Activation in Solid Tumor Radioresistance. J Oncol 2019;2019:5956867. [PMID: 31929797 DOI: 10.1155/2019/5956867] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
44 Zhou M, Chen QX, Yang YZ, Liang ZZ, Li YL, Huang ZY, Weng ZJ, Zhang XF, Guan JX, Tang LY, Ren ZF. Prognostic value of glutaminase 1 in breast cancer depends on H3K27me3 expression and menopausal status. Virchows Arch 2021. [PMID: 34562173 DOI: 10.1007/s00428-021-03210-6] [Reference Citation Analysis]
45 Noh S, Kim JY, Koo JS. Metabolic differences in estrogen receptor-negative breast cancer based on androgen receptor status. Tumour Biol 2014;35:8179-92. [PMID: 24850180 DOI: 10.1007/s13277-014-2103-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
46 Long JP, Li XN, Zhang F. Targeting metabolism in breast cancer: How far we can go? World J Clin Oncol 2016; 7(1): 122-130 [PMID: 26862496 DOI: 10.5306/wjco.v7.i1.122] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
47 Cha YJ, Kim ES, Koo JS. Amino Acid Transporters and Glutamine Metabolism in Breast Cancer. Int J Mol Sci 2018;19:E907. [PMID: 29562706 DOI: 10.3390/ijms19030907] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
48 Venmar KT, Kimmel DW, Cliffel DE, Fingleton B. IL4 receptor α mediates enhanced glucose and glutamine metabolism to support breast cancer growth. Biochim Biophys Acta 2015;1853:1219-28. [PMID: 25746764 DOI: 10.1016/j.bbamcr.2015.02.020] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]